NAMS Menopause Certification Master Practice Test | Comprehensive
Questions & Detailed Answers 2026/2027
Question 1
According to the Stages of Reproductive Aging Workshop + 10
(STRAW+10) staging system, which stage marks the beginning of the
early menopausal transition (Stage -2)?
• A. Persistent difference in consecutive cycle length of 7 days or
more
• B. An interval of amenorrhea of 60 days or longer
• C. Final menstrual period followed by 12 months of amenorrhea
• D. Stable regular cycles with normal FSH levels
Correct Answer: A. Persistent difference in consecutive cycle length of 7
days or more
Detailed Rationale: STRAW+10 Stage -2 (early menopausal transition) is
characterized by persistent differences in cycle length of 7 days or more,
whereas Stage -1 (late transition) involves skipped cycles or 60 days or
more of amenorrhea.
Question 2
What is the primary mechanism by which selective estrogen receptor
modulators (SERMs) such as raloxifene exert protective effects on the
skeletal system?
• A. Acting as an estrogen agonist on bone tissue to reduce bone
resorption and preserve mineral density
, • B. Stimulating direct osteoblastic proliferation through calcitonin
pathways
• C. Permanently blocking parathyroid hormone secretion
• D. Increasing renal tubular calcium excretion
Correct Answer: A. Acting as an estrogen agonist on bone tissue to
reduce bone resorption and preserve mineral density
Detailed Rationale: Raloxifene exhibits estrogen agonist activity in
bone, inhibiting osteoclast-mediated bone resorption and helping to
maintain bone density in postmenopausal women.
Question 3
Why does oral estrogen therapy produce a markedly higher risk of
venous thromboembolism (VTE) compared to transdermal estrogen
delivery?
• A. Oral estrogen bypasses the hepatic portal system entirely.
• B. First-pass hepatic metabolism of oral estrogen stimulates the
synthesis of coagulation factors and inflammatory markers.
• C. Transdermal patches contain direct anticoagulant molecules.
• D. Oral tablets instantly destroy circulating platelets.
Correct Answer: B. First-pass hepatic metabolism of oral estrogen
stimulates the synthesis of coagulation factors and inflammatory
markers.
Detailed Rationale: Oral estrogens undergo first-pass metabolism
through the liver, which significantly upregulates clotting factor
,production and inflammatory markers, elevating VTE risk. Transdermal
routes avoid this hepatic impact.
Question 4
Which lipid parameter is typically elevated as a direct metabolic
consequence of oral estrogen therapy?
• A. Serum triglycerides
• B. Low-density lipoprotein (LDL) cholesterol
• C. Total serum protein
• D. Fasting blood glucose
Correct Answer: A. Serum triglycerides
Detailed Rationale: First-pass hepatic effects of oral estrogen commonly
lead to an increase in serum triglyceride levels, whereas transdermal
estrogen avoids this hepatic alteration.
Question 5
What is the recommended duration of systemic hormone therapy for a
young woman diagnosed with premature ovarian insufficiency (POI)?
• A. Discontinue immediately upon diagnosis.
• B. Continue until the natural age of menopause (around age 51 to
52), at which point risks and benefits are re-evaluated.
• C. Limit treatment strictly to 6 months.
• D. Maintain therapy continuously until age 80 without review.
, Correct Answer: B. Continue until the natural age of menopause
(around age 51 to 52), at which point risks and benefits are re-
evaluated.
Detailed Rationale: Women with POI face prolonged hormone
deprivation; systemic hormone replacement is recommended until the
typical age of natural menopause to protect skeletal and cardiovascular
health.
Question 6
What is the primary clinical indication for adding a progestogen to
systemic estrogen therapy in a menopausal woman?
• A. To enhance the systemic absorption of the estrogen patch
• B. To prevent endometrial hyperplasia and carcinoma in women
with an intact uterus
• C. To lower serum cholesterol concentrations
• D. To stimulate basal metabolic rate and weight loss
Correct Answer: B. To prevent endometrial hyperplasia and carcinoma
in women with an intact uterus
Detailed Rationale: Unopposed estrogen stimulates the endometrium,
increasing the risk of hyperplasia and cancer. Progestogen counteracts
this proliferative effect.
Question 7
Which non-hormonal pharmaceutical agent is a selective neurokinin 3
(NK3) receptor antagonist used to treat vasomotor symptoms?
• A. Flibanserin
Questions & Detailed Answers 2026/2027
Question 1
According to the Stages of Reproductive Aging Workshop + 10
(STRAW+10) staging system, which stage marks the beginning of the
early menopausal transition (Stage -2)?
• A. Persistent difference in consecutive cycle length of 7 days or
more
• B. An interval of amenorrhea of 60 days or longer
• C. Final menstrual period followed by 12 months of amenorrhea
• D. Stable regular cycles with normal FSH levels
Correct Answer: A. Persistent difference in consecutive cycle length of 7
days or more
Detailed Rationale: STRAW+10 Stage -2 (early menopausal transition) is
characterized by persistent differences in cycle length of 7 days or more,
whereas Stage -1 (late transition) involves skipped cycles or 60 days or
more of amenorrhea.
Question 2
What is the primary mechanism by which selective estrogen receptor
modulators (SERMs) such as raloxifene exert protective effects on the
skeletal system?
• A. Acting as an estrogen agonist on bone tissue to reduce bone
resorption and preserve mineral density
, • B. Stimulating direct osteoblastic proliferation through calcitonin
pathways
• C. Permanently blocking parathyroid hormone secretion
• D. Increasing renal tubular calcium excretion
Correct Answer: A. Acting as an estrogen agonist on bone tissue to
reduce bone resorption and preserve mineral density
Detailed Rationale: Raloxifene exhibits estrogen agonist activity in
bone, inhibiting osteoclast-mediated bone resorption and helping to
maintain bone density in postmenopausal women.
Question 3
Why does oral estrogen therapy produce a markedly higher risk of
venous thromboembolism (VTE) compared to transdermal estrogen
delivery?
• A. Oral estrogen bypasses the hepatic portal system entirely.
• B. First-pass hepatic metabolism of oral estrogen stimulates the
synthesis of coagulation factors and inflammatory markers.
• C. Transdermal patches contain direct anticoagulant molecules.
• D. Oral tablets instantly destroy circulating platelets.
Correct Answer: B. First-pass hepatic metabolism of oral estrogen
stimulates the synthesis of coagulation factors and inflammatory
markers.
Detailed Rationale: Oral estrogens undergo first-pass metabolism
through the liver, which significantly upregulates clotting factor
,production and inflammatory markers, elevating VTE risk. Transdermal
routes avoid this hepatic impact.
Question 4
Which lipid parameter is typically elevated as a direct metabolic
consequence of oral estrogen therapy?
• A. Serum triglycerides
• B. Low-density lipoprotein (LDL) cholesterol
• C. Total serum protein
• D. Fasting blood glucose
Correct Answer: A. Serum triglycerides
Detailed Rationale: First-pass hepatic effects of oral estrogen commonly
lead to an increase in serum triglyceride levels, whereas transdermal
estrogen avoids this hepatic alteration.
Question 5
What is the recommended duration of systemic hormone therapy for a
young woman diagnosed with premature ovarian insufficiency (POI)?
• A. Discontinue immediately upon diagnosis.
• B. Continue until the natural age of menopause (around age 51 to
52), at which point risks and benefits are re-evaluated.
• C. Limit treatment strictly to 6 months.
• D. Maintain therapy continuously until age 80 without review.
, Correct Answer: B. Continue until the natural age of menopause
(around age 51 to 52), at which point risks and benefits are re-
evaluated.
Detailed Rationale: Women with POI face prolonged hormone
deprivation; systemic hormone replacement is recommended until the
typical age of natural menopause to protect skeletal and cardiovascular
health.
Question 6
What is the primary clinical indication for adding a progestogen to
systemic estrogen therapy in a menopausal woman?
• A. To enhance the systemic absorption of the estrogen patch
• B. To prevent endometrial hyperplasia and carcinoma in women
with an intact uterus
• C. To lower serum cholesterol concentrations
• D. To stimulate basal metabolic rate and weight loss
Correct Answer: B. To prevent endometrial hyperplasia and carcinoma
in women with an intact uterus
Detailed Rationale: Unopposed estrogen stimulates the endometrium,
increasing the risk of hyperplasia and cancer. Progestogen counteracts
this proliferative effect.
Question 7
Which non-hormonal pharmaceutical agent is a selective neurokinin 3
(NK3) receptor antagonist used to treat vasomotor symptoms?
• A. Flibanserin
